

Special Issue

Green Synthesis and Biological Evaluation of Quinazolinone-Based Compounds

Message from the Guest Editors

The conventional synthesis of different heterocycles often includes volatile organic solvents, catalysts, and energy consumption, causing the accumulation of large amounts of waste. In recent decades, green synthesis has utilized safer solvents, such as deep eutectic solvents, instead of harmful organic solvents.

Quinazolinones are a class of nitrogen-containing compounds with a broad spectrum of biological activities attributed to their interactions with enzymes, receptors, and DNA. Their potential in drug discovery continues to expand, so it is important to prepare novel derivatives.

This Special Issue highlights recent advances in the green synthesis of quinazolinone-based compounds. Also, we welcome submissions that cover biological activities, including antimicrobial, antiproliferative, antiradical, and anti-inflammatory effects, among others. Their potential activities can be predicted by computational studies. Therefore, the synthesis and biological activity of quinazolinone-based compounds are welcomed as topics in this Special Issue, taking both research papers and reviews into consideration for publication.

Guest Editors

Dr. Mario Komar

Dr. Marija Paurević

Dr. Maja Molnar

Deadline for manuscript submissions

closed (30 July 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/217875

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)